vs
Ouster, Inc.（OUST）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是Ouster, Inc.的1.2倍（$60.1M vs $48.6M），Ouster, Inc.净利率更高（8.2% vs -92.6%，领先100.8%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（83.8% vs 48.9%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（43.8% vs 34.2%）
Ouster, Inc.是总部位于美国加利福尼亚州旧金山的激光雷达技术企业，主打高分辨率数字化3D激光雷达传感器，产品广泛应用于自动驾驶车辆、工业自动化、机器人、无人机、地图测绘、国防及安防等领域。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
OUST vs RYTM — 直观对比
营收规模更大
RYTM
是对方的1.2倍
$48.6M
营收增速更快
RYTM
高出34.9%
48.9%
净利率更高
OUST
高出100.8%
-92.6%
两年增速更快
RYTM
近两年复合增速
34.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $48.6M | $60.1M |
| 净利润 | $4.0M | $-55.6M |
| 毛利率 | 42.9% | 88.1% |
| 营业利润率 | 17.6% | -87.1% |
| 净利率 | 8.2% | -92.6% |
| 营收同比 | 48.9% | 83.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.06 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OUSTRYTM
| Q1 26 | $48.6M | $60.1M | ||
| Q4 25 | $62.2M | $57.3M | ||
| Q3 25 | $39.5M | $51.3M | ||
| Q2 25 | $35.0M | $48.5M | ||
| Q1 25 | $32.6M | $32.7M | ||
| Q4 24 | $30.1M | $41.8M | ||
| Q3 24 | $28.1M | $33.3M | ||
| Q2 24 | $27.0M | $29.1M |
净利润OUSTRYTM
| Q1 26 | $4.0M | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-21.7M | $-52.9M | ||
| Q2 25 | $-20.6M | $-46.6M | ||
| Q1 25 | $-22.0M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-25.6M | $-43.6M | ||
| Q2 24 | $-23.9M | $-32.3M |
毛利率OUSTRYTM
| Q1 26 | 42.9% | 88.1% | ||
| Q4 25 | 60.2% | 91.6% | ||
| Q3 25 | 42.1% | 89.3% | ||
| Q2 25 | 45.2% | 88.6% | ||
| Q1 25 | 41.3% | 88.8% | ||
| Q4 24 | 43.8% | 90.9% | ||
| Q3 24 | 38.3% | 88.5% | ||
| Q2 24 | 33.7% | 89.9% |
营业利润率OUSTRYTM
| Q1 26 | 17.6% | -87.1% | ||
| Q4 25 | 1.5% | -82.2% | ||
| Q3 25 | -61.4% | -102.6% | ||
| Q2 25 | -76.5% | -93.4% | ||
| Q1 25 | -73.0% | -143.7% | ||
| Q4 24 | -85.1% | -98.6% | ||
| Q3 24 | -98.0% | -132.0% | ||
| Q2 24 | -93.6% | -139.2% |
净利率OUSTRYTM
| Q1 26 | 8.2% | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | -55.0% | -103.1% | ||
| Q2 25 | -58.8% | -96.1% | ||
| Q1 25 | -67.5% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -91.1% | -131.2% | ||
| Q2 24 | -88.4% | -110.9% |
每股收益（稀释后）OUSTRYTM
| Q1 26 | $0.06 | $-0.83 | ||
| Q4 25 | $0.10 | $-0.73 | ||
| Q3 25 | $-0.37 | $-0.82 | ||
| Q2 25 | $-0.38 | $-0.75 | ||
| Q1 25 | $-0.42 | $-0.81 | ||
| Q4 24 | $-0.46 | $-0.71 | ||
| Q3 24 | $-0.54 | $-0.73 | ||
| Q2 24 | $-0.53 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.1M | $340.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $275.6M | $122.9M |
| 总资产 | $381.5M | $442.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OUSTRYTM
| Q1 26 | $173.1M | $340.6M | ||
| Q4 25 | $208.6M | $388.9M | ||
| Q3 25 | $244.5M | $416.1M | ||
| Q2 25 | $226.5M | $291.0M | ||
| Q1 25 | $168.2M | $314.5M | ||
| Q4 24 | $172.0M | $320.6M | ||
| Q3 24 | $151.4M | $298.4M | ||
| Q2 24 | $184.2M | $319.1M |
股东权益OUSTRYTM
| Q1 26 | $275.6M | $122.9M | ||
| Q4 25 | $261.7M | $139.1M | ||
| Q3 25 | $247.4M | $148.8M | ||
| Q2 25 | $221.0M | $-11.9M | ||
| Q1 25 | $167.9M | $18.9M | ||
| Q4 24 | $180.9M | $21.7M | ||
| Q3 24 | $171.7M | $11.2M | ||
| Q2 24 | $170.6M | $39.3M |
总资产OUSTRYTM
| Q1 26 | $381.5M | $442.3M | ||
| Q4 25 | $349.5M | $480.2M | ||
| Q3 25 | $353.8M | $506.9M | ||
| Q2 25 | $321.8M | $372.7M | ||
| Q1 25 | $268.6M | $386.7M | ||
| Q4 24 | $276.1M | $392.3M | ||
| Q3 24 | $255.2M | $363.6M | ||
| Q2 24 | $309.9M | $381.8M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OUST
| Product revenue | $48.2M | 99% |
| Royalties | $347.0K | 1% |
RYTM
暂无分部数据
